Abstract:Summary Background Among people infected with measles in England between 2010 and 2019, the proportion of cases who had previously received two doses of vaccine has increased, especially among young adults. Possible explanations include rare infections in vaccinated individuals who did not gain immunity upon vaccination, made more common because fewer individuals in the population were born in the endemic era, before vaccination was introduced, and exposed as part of endemic transmission, or the waning of vaccine-induced immunity, which would present new challenges for measles control in near-elimination settings. We aimed to evaluate whether measles dynamics observed in England between 2010 and 2019 were in line with a waning of vaccine-induced immunity. Methods We used a compartmental mathematical model stratified by age group, region, and vaccine status, fitted to individual-level case data reported in England from 2010 to 2019 and collected by the UK Health Security Agency. The deterministic model was fitted using Monte Carlo Markov Chains under three scenarios: without the waning of vaccine-induced immunity, with waning depending on time since vaccination, and with waning depending on time since vaccination, starting in 2000. We generated stochastic simulations from the fitted parameter sets to evaluate which scenarios could replicate the transmission dynamics observed in vaccinated cases in England. Findings The scenario without waning overestimated the number of one-dose recipients among measles cases, and underestimated the number of two-dose recipients among cases older than 15 years (median 75 cases [95% simulation interval (SI) 44–124] in simulations without waning, 196 [95% SI 122–315] in simulations when waning was included, 188 [95% SI 118–301] in simulations when waning started in 2000, and 202 observed cases). The number of onward transmissions from vaccinated cases was 83% (95% credible interval 72–91%) of the number of transmissions from unvaccinated cases. The estimated waning rate was slow (0·039% per year of age; 95% credible interval 0·034–0·044% per year in the best-fitting scenario with waning starting in 2000), but sufficient to increase measles burden. Interpretation Measles case dynamics in England are consistent with scenarios assuming the waning of vaccine-induced immunity. Since measles is highly infectious, slow waning leads to a heightened burden in outbreaks, increasing the number of measles cases in people who are both vaccinated and unvaccinated. Our findings show that although the vaccine remains highly protective against measles infections for decades and most transmission is connected to people who are unvaccinated, breakthrough infections are increasingly frequent for individuals aged 15 years and older who have been vaccinated twice. Funding National Institute for Health and Care Research and Wellcome Trust.

Long-term dynamics of measles virus-specific neutralizing antibodies in children vaccinated before 12 months of age

The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review

Low titers of measles antibody in mothers whose infants suffered from measles before eligible age for measles vaccination

Dynamics of measles immunity from birth and following vaccination

Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study

Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens

Comparison of measles plaque reduction neutralization test (PRNT) and measles virus-specific IgG ELISA for assessment of immunogenicity of measles-mumps-rubella vaccination at 5-7 months of age and maternal measles antibodies

Long-term Neutralizing Antibody Levels Against Measles and Rubella Viruses Among Adults With 3 Doses of Measles-Mumps-Rubella Vaccine

Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity

Immunogenicity and reactogenicity following MMR vaccination in 5-7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants

Vaccine-induced neutralizing antibodies bind to the H protein of a historical measles virus

Formation of humoral and cellular immunity to measles vaccine in adults

The Effects of Vaccination Status and Age on Clinical Characteristics and Severity of Measles Cases in the United States in the Post-Elimination Era, 2001-2022

A real-world study on the changing characteristics of measles antibodies in premature infants in China

Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination

Waning immunity and potential asymptomatic infection in 3–7 years old children who received one dose of measles-mumps-rubella vaccine: A 4-year prospective study

Measles and Measles Vaccination: A Review

Humoral and cellular immunity to measles and rubella virus antigens in healthy subjects

Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study

Ongoing Measles in the Developed and Developing World

Measles, Mumps, and Rubella Revaccination in Children after Completion of Chemotherapy and Hematopoietic Stem Cell Transplantation: a Single-Center Prospective Efficacy and Safety Analysis